Type your tag names separated by a space and hit enter




Trade Name(s)

  • Karbinal ER

Ther. Class.
allergy, cold and cough remedies
none assigned

Pharm. Class.


Relief of allergic symptoms caused by histamine release including seasonal/perennial allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis (due to inhalant allergens or foods), mild/uncomplicated allergic skin conditions (urticaria or angioedema), dermatographism, as adjunctive management (with epinephrine and other standard acute treatments) of anaphylaxis, and to decrease severity of allergic reactions to blood/plasma


Antagonizes the effects of histamine at H1 –receptor sites; does not bind to or inactivate histamine. Significant CNS depressant and anticholinergic properties.

Therapeutic Effect(s):

Decreased symptoms of histamine excess (sneezing, rhinorrhea, nasal/ocular pruritus, ocular tearing/redness and skin itching/urticaria).


Absorption: Well absorbed following oral administration

Distribution: Unk

Metabolism and Excretion: Extensively metabolized by the liver, inactive metabolites excreted in urine. Negligable renal elimination of unchanged drug.

Half-life: 17 hr

TIME/ACTION PROFILE (antihistaminic effects)

POunk6.7 hr12 hr


Contraindicated in:

  • Hypersensitivity, including sulfite allergy
  • Lactation: Avoid if breast-feeding (risk of death in infant);
  • Concurrent use of MAOIs
  • Pedi: Children <2 yr (deaths have been reported).

Use Cautiously in:

  • Increased intraocular pressure or narrow angle glaucoma
  • Hyperthyroidism
  • Cardiovascular disease including hypertension
  • Stenosing peptic ulcer or pyloroduodenal obstruction
  • Symptomatic prostatic hypertrophy or bladder neck obstruction
  • Geri: Elderly may be more susceptible to adverse reactions;
  • OB: Use in pregnancy only if clearly needed
  • Pedi: Younger children may be more sensitive to sedation or excitation.

Adverse Reactions/Side Effects

CNS: dizziness, drowsiness, sedation

Resp: thickened bronchial secretions

GI: epigastric distress

Neuro: disturbed coordination

* CAPITALS indicate life-threatening.
Underline indicate most frequent.



  • Concurrent use with MAOIs may ↑ anticholinergic effects.
  • ↑ risk of CNS depression with other CNS depressants including alcohol, other antihistamines , opioid analgesics and sedative/hypnotics.


Use appropriate measuring device

PO: (Adults and Children ≥ 12 yr): 6–16 mg (7.5–20 mL) every 12 hr.

PO: (Children 2–11 yr): 0.2–0.4 mg/kg/day in divided doses every 12 hr; Children 6–11 yr– 6–12 mg (7.5–15 mL) every 12 hr; Children 4–5 yr– 3–8 mg (3.75–10 mL) every 12 hr; Children 2–3 yr– 3–4 mg (3.75–5 mL) every 12 hr.


Extended-release oral suspension (contains metabisulfite) (strawberry banana): 4 mg/5 mL


  • Assess allergy symptoms (rhinitis, conjunctivitis, hives) before and periodically during therapy
  • Assess lung sounds and character of bronchial secretions. Maintain fluid intake of 1500–2000 mL/day to decrease viscosity of secretions

Lab Test Considerations:

May case ↑ uric acid levels.

Potential Diagnoses


  • Begin with lowest dose and increase as needed and tolerated. Dose is based on condition severity and patient response.
  • PO: Administer twice daily.
    • Use a calibrated measuring device for accurate dose; household tablespoon is not accurate and could lead to overdose.

Patient/Family Teaching

  • Instruct patient to take medication as directed
  • May cause dizziness and drowsiness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known
  • Advise patient to avoid taking alcohol or other CNS depressants concurrently with this drug
  • Advise patient that good oral hygiene, frequent rinsing of mouth with water, and sugarless gum or candy may minimize dry mouth. Patient should notify dentist if dry mouth persists >2 wk
  • Instruct female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

Decrease in allergic symptoms

carbinoxamine is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Davis’s Drug Guide App + Web powered by Unbound Medicine provides up-to-date information on 5000+ trade name and generic drugs. View on the web or download App to your iPhone, iPad, or Android smartphone or tablet. Davis Drug Guide PDF. Learn more.


Quiring, Courtney, et al. "Carbinoxamine." Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. www.drugguide.com/ddo/view/Davis-Drug-Guide/109854/all/carbinoxamine.
Quiring C, Sanoski CA, Vallerand AH. Carbinoxamine. Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/109854/all/carbinoxamine. Accessed July 17, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). Carbinoxamine. In Davis's Drug Guide. Available from https://www.drugguide.com/ddo/view/Davis-Drug-Guide/109854/all/carbinoxamine
Quiring C, Sanoski CA, Vallerand AH. Carbinoxamine [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 July 17]. Available from: https://www.drugguide.com/ddo/view/Davis-Drug-Guide/109854/all/carbinoxamine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - carbinoxamine ID - 109854 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://www.drugguide.com/ddo/view/Davis-Drug-Guide/109854/all/carbinoxamine PB - F.A. Davis Company ET - 16 DB - Davis's Drug Guide DP - Unbound Medicine ER -